More on SNDX
Data
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $19.04 |
|
|||
| Open | $19.60 | ||||
| 52 Wk High | $18.03 | ||||
| 52 Wk Low | $8.97 | ||||
| Day High | $20.37 | ||||
| Day Low | $18.93 | ||||
| P/E | N/A | ||||
| EPS | $0.00 | ||||
| Volume | 3,994,897 | ||||
- Stifel Reiterates Buy Rating on Syndax Pharmaceuticals (SNDX)
- Form 4 Syndax Pharmaceuticals For: Jun 11 Filed by: Botwood Nicholas A.J.
- Form 144 Syndax Pharmaceuticals Filed by: Botwood Nicholas A.J.
- Syndax Pharmaceuticals (SNDX) PT Lowered to $31 at Guggenheim
- H.C. Wainwright Reiterates Buy Rating on Syndax Pharmaceuticals (SNDX)
- Form 144 Syndax Pharmaceuticals Filed by: Botwood Nicholas A.J.
- Syndax presents Revuforj clinical data across acute leukemia subtypes
- Syndax Showcases Revuforj® (revumenib) Clinical Activity in Multiple Acute Leukemia Subtypes and Settings at EHA 2026
- Syndax publishes SAVE trial data on Revuforj combination therapy in AML
- Syndax Announces Publication of SAVE Data on Revuforj® (revumenib) in Combination with Decitabine/Cedazuridine and Venetoclax in Relapsed/Refractory NPM1m, KMT2Ar, and NUP98r AML in the Journal of Cl
Entities mentioned with SNDX
- FDA | View Related Stories »
- Twitter | View Related Stories »
- Earnings | View Related Stories »
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- ARK | View Related Stories »
- 13G | View Related Stories »
- PDUFA | View Related Stories »
- Show More...
